| |
|
|
|
|
Useful links
|
| |
|
This list includes just some of the organizations that offer additional information about bacterial vaginosis and women’s healthcare.
|
| |
American College of Obstetricians and Gynecologists (ACOG)—Founded in 1951, ACOG is the nation’s leading group of professionals providing healthcare for women. The nonprofit group’s website offers extensive information and industry news for professionals that cover topics such as practice management, medical advances, continuing education, and advocacy work.
www.acog.org
OBGYN.net—This resource was created to meet the needs of obstetrics and gynecology professionals, the medical industry, and women. Offering informational resources similar to those available at a medical conference or symposium, the website provides numerous services and a broad array of up-to-date information.
www.obgyn.net
National Women’s Health Information Center—Established by the US Department of Health and Human Services, this website and toll-free call center provides information for healthcare professionals on a wide range of health topics specific to women.
www.4woman.gov/HealthPro/
Contemporary OB/GYN®—This website tracks key scientific advances and provides information on how they may be applied in your practice. Site resources include clinical articles, news, and continuing medical education.
www.contemporaryobgyn.net
Medscape® Ob/Gyn and Women’s Health—Medscape® is one of the most robust and integrated medical information and educational tools available on the Internet. Accessible with free registration, the Ob/Gyn and Women’s Health section is devoted to clinical journal articles, conference coverage, news, and numerous CME activities for Ob/Gyn healthcare professionals.
www.medscape.com/womenshealthhome
|
| |
|
Additional resources
|
| |
Centers for Disease Control and Prevention
www.cdc.gov
Gynazole-1®
www.gynazole-1.com
Estronaut
www.estronaut.com
ezyhealth.com
www.ezyhealth.com/
InteliHealth
www.intelihealth.com/IH/ihtIH/WSIHW000/408/408.html
iVillageHealth
health.ivillage.com/?ice=iv,mp,bu,hw
MedicineNet.com
www.medicinenet.com/script/main/hp.asp
Teenwire
www.teenwire.com
WebMD
www.webmd.com
|
| |
|
|
Clindesse® (clindamycin phosphate) Vaginal Cream, 2%, is indicated for the treatment of bacterial
vaginosis in non-pregnant women. Clindesse is Pregnancy Category B, which means there are no
adequate and well-controlled studies in pregnant women. Therefore, Clindesse should be used
during pregnancy only if clearly needed.
|
| |
|
Note: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined
by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells.
|
|
|
Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans, and Herpes simplex virus, should be ruled out.
|
| |
| Important Safety Information |
| |
|
Clindesse is contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin, or any of the components of this vaginal cream, and in individuals with a history of regional enteritis, ulcerative colitis, or a history of “antibiotic-associated” colitis.
|
| |
|
This cream contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, the use of such barrier contraceptives is not recommended concurrently or for 5 days following treatment with Clindesse. During this time period, condoms may not be reliable for preventing pregnancy or for protecting against transmission of HIV and other sexually transmitted diseases.
|
| |
|
Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin. Orally and parenterally administered clindamycin has been associated with severe colitis. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of Clindesse, even though there is minimal systemic absorption of clindamycin from the vagina with administration of Clindesse Vaginal Cream.
|
| |
|
In clinical trials (n=368), 1.6% of patients discontinued therapy due to adverse events. The most frequently reported adverse events were vaginosis fungal (14.1%), vulvovaginal pruritus (3.3%), and headache (2.7%).
|
| |
|
|
|
|